 | Up a level |
Kremsner, Peter G., Ahuad Guerrero, Rodolfo Andres, Arana-Arri, Eunate 
ORCID: 0000-0001-9759-333X, Aroca Martinez, Gustavo Jose, Bonten, Marc, Chandler, Reynaldo, Corral, Gonzalo, Louis De Block, Eddie Jan, Ecker, Lucie, Justin Gabor, Julian, Garcia Lopez, Carlos Alberto, Gonzales, Lucy, Granados Gonzalez, Maria Angelica, Gorini, Nestor, Grobusch, Martin P., Hrabar, Adrian D., Junker, Helga, Kimura, Alan, Lanata, Claudio F., Lehmann, Clara, Leroux-Roels, Isabel ORCID: 0000-0002-5084-4696, Mann, Philipp, Fernando Martinez-Resendez, Michel, Ochoa, Theresa J., Alberto Poy, Carlos, Reyes Fentanes, Maria Jose, Rivera Mejia, Luis Maria, Ruiz Herrera, Vida Veronica, Saez-Llorens, Xavier, Schoenborn-Kellenberger, Oliver, Schunk, Mirjam, Sierra Garcia, Alexandra, Vergara, Itziar ORCID: 0000-0001-9671-7898, Verstraeten, Thomas, Vico, Marisa and Oostvogels, Lidia
(2022).
Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial.
Lancet Infect. Dis., 22 (3).
S. 329 - 341.
OXFORD:
ELSEVIER SCI LTD.
ISSN 1474-4457